X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (2648) 2648
mice (2009) 2009
humans (1665) 1665
osteoclasts - drug effects (1434) 1434
rank ligand - metabolism (1307) 1307
osteoclasts - metabolism (1072) 1072
cell differentiation - drug effects (1020) 1020
osteoclasts - cytology (1017) 1017
male (993) 993
cells, cultured (977) 977
female (919) 919
rank ligand (869) 869
rankl (816) 816
osteoprotegerin (788) 788
differentiation (763) 763
rank ligand - pharmacology (735) 735
osteoporosis (687) 687
receptor activator of nuclear factor-kappa b (668) 668
osteoclast (656) 656
expression (617) 617
osteoclastogenesis (603) 603
receptor activator (594) 594
cell line (576) 576
mice, inbred c57bl (544) 544
cell biology (537) 537
rank ligand - genetics (533) 533
bone resorption (530) 530
osteogenesis - drug effects (516) 516
osteoclasts (507) 507
biochemistry & molecular biology (494) 494
cells (489) 489
endocrinology & metabolism (488) 488
osteoblasts - drug effects (476) 476
osteoblasts - metabolism (459) 459
bone-resorption (442) 442
pharmacology & pharmacy (432) 432
osteoprotegerin - metabolism (431) 431
rats (427) 427
signal transduction - drug effects (423) 423
nf-kappa b - metabolism (420) 420
activation (409) 409
nf-kappa-b (397) 397
gene expression (384) 384
bone (377) 377
musculoskeletal diseases (376) 376
cell differentiation (357) 357
osteoclasts - physiology (356) 356
signal transduction (355) 355
osteoclast differentiation (352) 352
trance protein (350) 350
in-vitro (347) 347
bone resorption - metabolism (336) 336
rna, messenger - metabolism (333) 333
osteoclasts - pathology (326) 326
gene expression regulation - drug effects (322) 322
analysis (311) 311
tartrate-resistant acid phosphatase (310) 310
ligand (303) 303
macrophages - drug effects (300) 300
osteoblasts (298) 298
rank ligand - antagonists & inhibitors (297) 297
immunology (295) 295
macrophage colony-stimulating factor - pharmacology (291) 291
nfatc transcription factors - metabolism (289) 289
bone marrow cells - cytology (285) 285
dose-response relationship, drug (284) 284
kappa-b ligand (283) 283
inflammation (275) 275
denosumab (266) 266
bone resorption - pathology (262) 262
reverse transcriptase polymerase chain reaction (260) 260
osteoblasts - cytology (253) 253
membrane glycoproteins - metabolism (247) 247
membrane glycoproteins - pharmacology (247) 247
bone marrow cells - drug effects (243) 243
cytokines (242) 242
carrier proteins - pharmacology (241) 241
dentistry (240) 240
osteoprotegerin - genetics (240) 240
bone loss (236) 236
carrier proteins - metabolism (234) 234
gene-expression (234) 234
medicine, research & experimental (233) 233
coculture techniques (231) 231
bone density - drug effects (228) 228
macrophages - metabolism (228) 228
receptor (228) 228
resorption (227) 227
rna, messenger - genetics (224) 224
dentistry, oral surgery & medicine (222) 222
macrophages (222) 222
rheumatoid-arthritis (222) 222
apoptosis (221) 221
ligands (221) 221
receptor activator of nuclear factor-kappa b - metabolism (221) 221
bones (220) 220
bone resorption - drug therapy (217) 217
bone density conservation agents - pharmacology (215) 215
middle aged (215) 215
proteins (213) 213
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3503) 3503
Japanese (63) 63
Chinese (62) 62
Portuguese (7) 7
French (5) 5
Russian (4) 4
Hungarian (3) 3
Polish (3) 3
German (2) 2
Spanish (2) 2
Croatian (1) 1
Danish (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
...B ligand, on bone mineral density and fractures in such men. Use of denosumab was associated with increased bone mineral density at all sites and reduction in the incidence of new vertebral fractures... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 22, pp. 1665 - 1675
Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These... 
GROWTH-FACTOR RECEPTOR | CONTROLLED-TRIAL | ANTIANGIOGENIC THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | BONE METASTASES | C-MET | SIPULEUCEL-T APC8015 | ABIRATERONE ACETATE | TUMOR MICROENVIRONMENT | ANGIOGENESIS INHIBITION | Cancer Vaccines - pharmacology | Humans | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Prostatic Neoplasms - immunology | RANK Ligand - pharmacology | Receptors, Androgen - drug effects | Treatment Failure | Prostatic Neoplasms - drug therapy | Phenylthiohydantoin - pharmacology | Tumor Microenvironment - drug effects | Dasatinib | Antibodies, Monoclonal - pharmacology | Angiogenesis Inhibitors - pharmacology | Clusterin - pharmacology | Pyrimidines - pharmacology | Denosumab | Prostate-Specific Antigen - blood | Orchiectomy | Signal Transduction - drug effects | Anilides - pharmacology | Mice | Receptor Cross-Talk - drug effects | Endothelin-1 - antagonists & inhibitors | Immunotherapy - methods | Taxoids - pharmacology | Ipilimumab | Tissue Extracts - pharmacology | Bone Remodeling - drug effects | Pyrrolidines - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Mice, SCID | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Xenograft Model Antitumor Assays | Cancer Vaccines - immunology | Pyrroles - pharmacology | Animals | RANK Ligand - antagonists & inhibitors | Pyridines - pharmacology | Thiazoles - pharmacology | Immune response | Development and progression | Cellular signal transduction | Research | Drug therapy | Health aspects | Prostate cancer | Risk factors | Review
Journal Article
Journal Article
Journal Article
Journal of endodontics, ISSN 0099-2399, 2013, Volume 39, Issue 12, pp. 1557 - 1561
... osteoclasts and osteoblasts (3) . In several studies, identified receptor activators of nuclear factor kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) have been shown... 
Endocrinology & Metabolism | Dentistry | mineral trioxide aggregate | TRAP | receptor activator for nuclear factor kappaB | RAW 264.7 macrophages | Calcium silicate cement | OSTEOBLAST | CELLS | RANKL | CEMENT | receptor activator for nuclear factor kappa B | RATIO | DENTISTRY, ORAL SURGERY & MEDICINE | CALCIUM | EXPRESSION | COMMUNICATION | Spectrophotometry, Atomic - methods | Cathepsin K - drug effects | Tartrate-Resistant Acid Phosphatase | TNF Receptor-Associated Factor 6 - antagonists & inhibitors | Dose-Response Relationship, Drug | Silicon - pharmacology | Culture Media | Cell Culture Techniques | Cell Death - drug effects | Acid Phosphatase - drug effects | Oxides - administration & dosage | Calcium Compounds - pharmacology | Silicates - pharmacology | Cell Line | Cell Survival - drug effects | NF-kappa B - antagonists & inhibitors | Materials Testing | Calcium Compounds - administration & dosage | Silicon - administration & dosage | Oxides - pharmacology | Animals | Aluminum Compounds - administration & dosage | RANK Ligand - antagonists & inhibitors | Cell Differentiation - drug effects | Silicates - administration & dosage | Macrophages - drug effects | Silicate Cement - pharmacology | Aluminum Compounds - pharmacology | Cell Proliferation - drug effects | Isoenzymes - drug effects | Mice | Silicate Cement - administration & dosage | Drug Combinations | Osteoclasts - drug effects | Medical colleges
Journal Article
PloS one, ISSN 1932-6203, 2017, Volume 12, Issue 7, p. e0181126
... to impaired osteoclastogenesis due to the reduced expression of receptor activator of nuclear factor-.B ligand (RANKL... 
TRABECULAR BONE | CELLS | CYTOKINES | BONE-FORMATION | SIGNALING PATHWAY | MULTIDISCIPLINARY SCIENCES | RECEPTOR | DIFFERENTIATION | KNOCKOUT MICE | ARTHRITIS | INTERLEUKIN-6 | RANK Ligand - metabolism | Coculture Techniques | Male | Azetidines - pharmacology | Recombinant Proteins - biosynthesis | Recombinant Proteins - isolation & purification | Janus Kinase 1 - metabolism | RANK Ligand - pharmacology | RNA Interference | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | Bone Marrow Cells - drug effects | Interleukin-11 - secretion | Osteoblasts - cytology | Interleukin-6 - metabolism | Janus Kinase 2 - antagonists & inhibitors | Cell Survival - drug effects | Dinoprostone - pharmacology | Bone Marrow Cells - cytology | Osteoblasts - drug effects | Osteogenesis - drug effects | Janus Kinase 2 - genetics | Interleukin-11 - metabolism | Macrophage Colony-Stimulating Factor - metabolism | Recombinant Proteins - pharmacology | Down-Regulation - drug effects | Janus Kinase 1 - antagonists & inhibitors | Sulfonamides - pharmacology | Interleukin-6 - secretion | RANK Ligand - genetics | Animals | Cell Differentiation - drug effects | Mice | Osteoblasts - metabolism | Bone Marrow Cells - metabolism | Cholecalciferol - pharmacology | Enzymes | Cellular signal transduction | Genetic aspects | Regulation | Gene expression | Phosphotransferases | Health aspects | Cell culture | Leukemia | Interleukin | Calcitriol | Arthritis | Biochemistry | Bone diseases | Kinases | Macrophages | Osteoblasts | Bone surgery | Interleukin 6 | Osteoporosis | Signal transduction | Receptors | Biomedical materials | Dihydroxyvitamin D3 | Janus kinase 2 | Bone marrow | Janus kinase | Biocompatibility | Colony-stimulating factor | Inhibition | Cytokines | Leukemia inhibitory factor | Macrophage colony-stimulating factor | Interleukin 11 | Bone turnover | Metabolism | Osteoclastogenesis | Calvaria | Osteoblastogenesis | Inhibitors | Rheumatoid arthritis | Orthopedics | Osteoclasts | Receptor mechanisms | Differentiation | In vitro methods and tests
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 07/2000, Volume 15, Issue 7, pp. 1321 - 1329
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2000, Volume 106, Issue 12, pp. 1481 - 1488
... (ligand for the receptor activator of NF-kappaB) required to induce osteoclast formation... 
MEDICINE, RESEARCH & EXPERIMENTAL | TUMOR-NECROSIS-FACTOR | DESTRUCTION | MECHANISM | RECEPTOR | OSTEOPROTEGERIN | EXPRESSION | BONE-RESORPTION | OSTEOBLASTIC CELLS | BETA
Journal Article
Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 8, pp. 933 - 939
Individuals who have mutations in the breast-cancer-susceptibility gene BRCA1 (hereafter referred to as BRCA1-mutation carriers) frequently undergo... 
BRCA2 MUTATION CARRIERS | MEDICINE, RESEARCH & EXPERIMENTAL | TUMOR-DEVELOPMENT | BIOCHEMISTRY & MOLECULAR BIOLOGY | PROLIFERATION | OVARIAN-CANCER | CELL BIOLOGY | RISK-REDUCING SURGERY | STEM-CELL | MICE | DIFFERENTIAL EXPRESSION ANALYSIS | GLAND | MAMMARY EPITHELIAL-CELLS | Immunohistochemistry | Neoplasm Transplantation | RANK Ligand - metabolism | Humans | Molecular Targeted Therapy | Prophylactic Mastectomy | Stem Cells - metabolism | Breast - metabolism | Breast Neoplasms - metabolism | Denosumab - therapeutic use | Flow Cytometry | Organoids - metabolism | Female | Receptor Activator of Nuclear Factor-kappa B - metabolism | Disease Models, Animal | Carcinogenesis - genetics | Bone Density Conservation Agents - therapeutic use | Reverse Transcriptase Polymerase Chain Reaction | Bone Density Conservation Agents - pharmacology | Breast Neoplasms - prevention & control | Carcinogenesis - drug effects | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Animals | Breast Neoplasms - genetics | RANK Ligand - antagonists & inhibitors | Breast - drug effects | DNA Repair | Organoids - drug effects | Pilocarpine - analogs & derivatives | Stem Cells - drug effects | Heterozygote | Cell Proliferation - drug effects | Mice | Mutation | Denosumab - pharmacology | Tumor Suppressor Proteins | Care and treatment | Cytokines | BRCA mutations | Development and progression | Breast cancer | Genetic aspects | Health aspects | Ligands | Genes
Journal Article
Journal Article